Success Metrics

Clinical Success Rate
63.6%

Based on 7 completed trials

Completion Rate
64%(7/11)
Active Trials
0(0%)
Results Posted
86%(6 trials)
Terminated
4(36%)

Phase Distribution

Ph phase_1
4
36%
Ph phase_2
7
64%

Phase Distribution

4

Early Stage

7

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
4(36.4%)
Phase 2Efficacy & side effects
7(63.6%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

63.6%

7 of 11 finished

Non-Completion Rate

36.4%

4 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(7)
Terminated(4)

Detailed Status

Completed7
Terminated4

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
63.6%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (36.4%)
Phase 27 (63.6%)

Trials by Status

completed764%
terminated436%

Recent Activity

0 active trials
Showing 5 of 11
terminatedphase_1

Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1

NCT04874194
completedphase_2

Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML

NCT00462943
completedphase_2

Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation

NCT00375219
terminatedphase_1

A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)

NCT02078960
terminatedphase_1

AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients

NCT02440568
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT04874194Phase 1

Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1

Terminated
NCT00462943Phase 2

Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML

Completed
NCT00375219Phase 2

Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation

Completed
NCT02078960Phase 1

A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)

Terminated
NCT02440568Phase 1

AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients

Terminated
NCT02029417Phase 2

Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Terminated
NCT01844869Phase 1

An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate

Completed
NCT00003694Phase 2

Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase

Completed
NCT00002574Phase 2

Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

Completed
NCT00006364Phase 2

Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

Completed
NCT00003239Phase 2

Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11